{
    "nct_id": "NCT03495609",
    "official_title": "The Use of Recombinant hCG to Prevent Breast Cancer in BRCA1 and BRCA2 Carriers",
    "criteria": {
        "raw_text": "Inclusion Criteria:\n\n* premenopausal women\n* BRCA1 carrier\n\nExclusion Criteria:\n\n* History of allergic reaction to compounds of similar chemical or biologic composition to hCG\n* receiving medication that could interfere with the study protocol objectives (hormonal contraceptives, androgens, prednisone, thyroid hormones, insulin)\n* previous treatment with follicle stimulating hormone for assisted reproduction\n* uncontrolled intercurrent illness\n* Heart disease\n* Severe cognitive decline\n* Psychiatric desease\n* HIV positive\n* Hepatitis B or C infection\n\nsex: FEMALE\n\nminimumAge: 18 Years\n\nmaximumAge: 30 Years\n\nstdAges: ['ADULT']",
        "inclusion": "* premenopausal women\n* BRCA1 carrier\n\nsex: FEMALE\n\nminimumAge: 18 Years\n\nmaximumAge: 30 Years\n\nstdAges: ['ADULT']",
        "exclusion": "* History of allergic reaction to compounds of similar chemical or biologic composition to hCG\n* receiving medication that could interfere with the study protocol objectives (hormonal contraceptives, androgens, prednisone, thyroid hormones, insulin)\n* previous treatment with follicle stimulating hormone for assisted reproduction\n* uncontrolled intercurrent illness\n* Heart disease\n* Severe cognitive decline\n* Psychiatric desease\n* HIV positive\n* Hepatitis B or C infection"
    }
}